

AdMeTech Foundation's GPS 2026:
Guiding the Future of Precision Care

SCIENTIFIC PROGRAM

(Preliminary Draft – July 16, 2026)

(The Current Sessions and Presentations are in Eastern Standard Time and Subject to Change)

TUESDAY, OCTOBER 6, 2026

- 8:00AM WELCOME AND INTRODUCTION**
Faina Shtern, MD, President and CEO, AdMeTech Foundation
- 8:15AM SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION**
- Moderators:**
- Peter Albers, MD, Chairman, Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf and Division Head, Division of Personalized Early Detection of Prostate Cancer at the German Cancer Research Center (DKFZ), Heidelberg University, Germany
- Sigrid Carlsson, MD, PhD, MPH, Division Head, Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg University, Germany
- Stenio Zequi, MD, MSc, PhD, Head of Referral Center for Urological Tumors, A.C. Camargo Cancer Center, Brazil
- 8:30AM Topic 1: State of the Art and Future Directions in “Smart” Prostate Cancer Screening**
- 8:30AM Topic 1A: Advancing Risk-Stratified Screening and Early Detection:** Sigrid Carlsson, MD, PhD, MPH
- 8:40AM Q & A**
- 8:42AM Topic 1B: Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50):** Peter Albers, MD
- 8:52AM Q & A**
- 8:54AM Topic 1C: Overview and Update on ERSPC, PIAS, and PRAISE-U Clinical Trials:** Roderick CN van den Bergh, MD, PhD, Department of Urology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands
- 9:04AM Topic 1D: Organized Prostate Testing (OPT) in Sweden:** Anders Bjartell, MD, PhD, FEBU, Professor in Urology, Department of Translational Medicine, Lund University; and Senior Consultant, Skane University Hospital, Sweden
- 9:14AM Q & A**
- 9:16AM Topic 1E: Update on TRANSFORM - National UK Trial of Prostate Cancer Screening:** Rhian Gabe, PhD, Professor of Biostatistics and Clinical Trials, Director of Barts Clinical Trials Units, Wolfson Institute of Population Health, Queen Mary University of London, United Kingdom
- 9:26AM Q & A**
- 9:28AM Topic 1F: Update on PROSCREEN: A Randomized Population-Based Screening Trial Combining PSA, Kallikrein Panel and MRI:** Anssi Auvinen, MD, PhD, Professor and Head, Department of Epidemiology, Tampere University, Finland
- 9:38AM Q & A**
- 9:40AM-10:00AM Panel Discussion: “Smart” Prostate Cancer Screening**

10:00AM-10:30AM	COFFEE BREAK
10:30AM	SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
	Moderators:
	Preston Sprenkle, MD, Associate Professor of Surgery, Yale University School of Medicine; and Vice Chair, NCCN Prostate Cancer Early Detection Panel
	Clare M. C. Tempany-Afdhal, MB, BAO, BCh, Ferenc Jolesz MD Professor of Radiology, Harvard Medical School; Scientific Director of Clinical and Translational research MGB, Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Immediate Past Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS
10:30AM	Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
10:30AM	<i>Topic 2A: Current and Emerging Liquid Diagnostics</i>
10:30AM	Overview of Liquid Biomarkers: E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, <i>Oncology Journal</i>
10:40AM	Q & A
10:42AM	Large-Scale, Prospective, Clinical Validation Study of the Diagnostic Performance of IsoPSA Without and In Combination with Mutli-Parametric MRI for the Detection of High-Grade Prostate Cancer: Mark Stovsky, MD, MBA, FACS, Chief Medical Officer, Cleveland Diagnostics, Inc.
10:48AM	Q & A
10:50AM	<i>Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies</i>
10:50AM	OPTIMUM Trial – A 3-Arm Randomized Controlled Clinical Study Evaluating the Role of Micro-Ultrasound in Men with Clinical Suspicion of Prostate Cancer: Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation
11:00AM	Q & A
11:02AM	MRI PI-RADS Standardization and Clinical Evaluation: Clare M. C. Tempany-Afdhal, MB, BAO, BCh
11:12AM	Q & A
11:14AM	Towards Reproducible Prostate MRI Across Scanners and Sites: Preliminary Clinical Evidence for Concurrent ADC Calibration Using METRION: Xavier Golay, PhD, MS, Honorary Professor of MRI Physics, University College London, UK
11:24AM	Q & A
11:26AM	<i>Topic 2C: State of the Art and Future Directions in Prostate Biopsies</i>
11:26AM	Role of MRI-Targeted Biopsy in Optimizing Prostate Cancer Diagnosis: Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University
11:36AM	Q & A
11:38AM	<i>Topic 2D: Do Biopsies Account for Some of the Progression We See After Prostate Cancer Treatments?</i> Mark Emberton, MD, Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom
11:48AM	Q & A
11:50AM-12:30PM	<i>Panel Discussion: Current and Emerging Diagnostic Tools</i>

12:30PM	Topic 3: Newly Identified Mutations Associated with Prostate Cancer Risk and Aggressiveness: Brian T. Helfand, MD, PhD, Ronald L. Chez Family and Richard Melman Family Endowed Chair in Prostate Cancer, and Clinical Professor, University of Chicago, Pritzker School of Medicine, NorthShore University HealthSystem, Endeavor Health
12:40PM	Q & A
12:42PM	Topic 4: NCCN Guidelines for Early Detection of Prostate Cancer: Preston Sprenkle, MD
12:52PM	Q & A
12:54PM-1:30PM	General Discussion – Moderators and Speakers
1:30PM-2:00PM	VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)
2:00PM-3:00PM	LUNCH BREAK
3:00PM	KEYNOTE PRESENTATIONS
3:00PM	NCCN Guidelines for Prostate Cancer Treatment: Mack Roach III MD, FACR, FASTRO, FASCO, Professor of Radiation Oncology and Urology and Director, Particle Therapy Research Program & Outreach, Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center
3:15PM	Q & A
3:20PM	Precision Care and Health Disparities in Black Men: Adam B. Murphy, MD, MBA, MSCI, Distinguished Professor of Population Health Research in Urology, Department of Urology and Preventive Medicine, Northwestern Medicine - Feinberg School of Medicine
3:35PM	Q & A
3:40PM	PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT Moderators: Paul Boutros, PhD, MBA, Professor of Cancer Genetics & Epigenetics and Director, Cancer Center; and Vice President, Data Science & AI, Sanford Burnham Prebys Medical Discovery Institute Amita Shukla-Dave, PhD, Vice-Chair, Radiology-Medical Physics Outreach; Deputy Service Chief for Predictive Informatics, and Director of Quantitative Imaging, Department of Radiology, Memorial Sloan Kettering Cancer Center
3:50PM	<i>The Evolution of AI Tooling: Should I Be Scared Yet?:</i> Paul Boutros, PhD, MBA
4:00PM	Q & A
4:02PM	<i>AI, Bioinformatics and Prostate Cancer Care:</i> Ilya Gipp, MD, PhD, Chief Medical Officer - Oncology, GE Healthcare (TBC)
4:12PM	Q & A
4:14PM	<i>AI for MR Scanning and Disease Prediction:</i> Angela Tong, MD, Abdominal Radiologist, Grossman School of Medicine, New York University
4:24PM	Q & A
4:26PM	<i>Racially-Associated MRI Analysis and Modeling for Predicting Aggressive Prostate Cancer:</i> Kyung Sung, PhD, Professor of Radiological Sciences, Magnetic Resonance Research Labs, David Geffen School of Medicine, University of California, Los Angeles
4:36PM	Q & A
4:38PM	<i>AI in Surgery and Pathology for Prostate Cancer:</i> Saad Nadeem, PhD, Associate Attending Computer Scientist, Department of Medical Physics, Memorial Sloan Kettering Cancer Center

4:48PM	Q & A
4:50PM	<i>AI and Multi-Modality Diagnostics for Prostate Cancer:</i> Francisco Sanchez-Vega, PhD, Assistant Attending, Computational Oncology Service, Department of Epidemiology and Biostatistics; and Head of Real-World Data Analysis, Halvorsen Center for Computational Oncology, Memorial Sloan Kettering Cancer Center
5:00PM	Q & A
5:02PM-5:30PM	<i>Panel Discussion: Moderators and Speakers</i>
5:30PM-6:00PM	GENERAL DISCUSSION
WEDNESDAY, OCTOBER 7, 2026	
8:00AM	SESSION II (PART 1). CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
	Moderators:
	Mohammed Shahait, MD, Assistant Professor of Clinical Urology, Department of Urology, University of California, Irvine
	Lalitha K. Shankar, Acting Associate Director, Cancer Imaging Program; and Chief, Clinical Trials Branch, National Cancer Institute, National Institutes of Health
8:05AM	Topic 1: Multiomics for Prostate Cancer
8:05AM	<i>Topic 1A: Prostate Cancer Imaging</i>
8:05AM	<i>PRIMARY2 Clinical Trial - PSMA PET/CT as a "Manogram" to Improve Prostate Cancer Diagnosis:</i> Professor Michael Hofman, MBBS, FRACP, FAANMS, FICIS, FSNM, FAHMS, GAICD, PET/CT Head, Cancer Imaging; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC); Peter MacCallum Cancer Centre, Melbourne; and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia
8:15AM	Q & A
8:17AM	<i>Total-Body PSMA-PET vs. Short-Axial Field-of-View Conventional PSMA-PET in Patients with Biochemical Recurrence:</i> Andrea Di Giorgio, MD, Nuclear Medicine Unit - University of Bologna, and University of Bologna Medical Center, Italy
8:27AM	Q & A
8:29AM	<i>Micro-Ultrasound in Prostate Cancer: Role in Biopsy-Naive Patients, Decisions to Biopsy, and Active Surveillance:</i> Adam Kinnaird, MD, PhD, Frank and Carla Sonjonky Chair of Prostate Cancer Research, Departments of Surgery, Oncology, Radiology and Diagnostic Imaging, University of Alberta, Canada
8:39AM	Q & A
8:41AM	<i>Topic 1B: Clinical and Prognostic Implications of Cancer Visibility on Imaging</i>
8:41AM	<i>Radiologic Perspective:</i> Sungmin Woo, MD, PhD, Assistant Professor, Department of Radiology, Grossman School of Medicine, New York University
8:51AM	Q & A
8:53AM	<i>Urologic Perspective: Genomics and Natural History of MRI Invisible vs Visible Cancers:</i> Laurence Klotz, MD
9:03AM	Q & A
9:05AM	<i>Topic 1C: Novel and Emerging Pathological Factors in Localized and Recurrent Prostate Cancer:</i> Gladell P. Paner, MD, Professor of Pathology and Surgery (Urology), and Director of Genitourinary Pathology Service, University of Chicago
9:15AM	Q & A
9:17AM	<i>Topic 1D: ProQuant Update – Gleason Pattern 4 for Risk Stratification:</i> Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center

9:27AM	Q & A
9:29AM	<i>Topic 1E: Integration of MRI with Histology, Genomics, and Proteomics:</i> Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA
9:39AM	Q & A
9:41AM-10:00AM	<i>Panel Discussion: Multiomics – Moderators and Speakers</i>
10:00AM-10:30AM	COFFEE BREAK
10:30AM	SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
	Moderators:
	Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF (TBC)
	Raja B. Khaulil, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign
	Jane Nguyen, MD, PhD, Assistant Professor of Pathology at Case Western Reserve University/Lerner College of Medicine; Director of Genitourinary Pathology; Staff Pathologist in the Diagnostics Institute, Department of Pathology and Laboratory Medicine at Cleveland Clinic
10:30AM	Topic 2: Year in Review - Emerging Advances in Diagnosis and Treatment: Matthew Cooperberg, MD, MPH (TBC)
10:40AM	Q & A
10:42AM	Topic 3: Beyond the Grade: Histology-Driven Risk Stratification in Prostate Cancer: Jane Nguyen, MD, PhD
10:52AM	Q & A
10:54AM	Topic 4: The Future of PSMA PET Imaging: Ashley E. Ross, MD, PhD, Associate Professor of Urology and Clinical Director, Polsky Urologic Oncology Center, Northwestern Feinberg School of Medicine. Sponsored by Blue Earth Diagnostics.
11:04AM	Q & A
11:06AM	Topic 5: Integration of Precision Diagnosis and Precision Treatment
11:06AM	<i>Topic 5A: Integrated Diagnostics (Radiogenomics) for Active Surveillance, Surgical and Radiation Treatment:</i> Sanoj Punnen, MD, MAS, MBA, Professor of Urology, and Vice Chair of Research, Desai Sethi Urology Institute; and Assistant Director of Clinical Research and Cancer Control Research Program Co-Lead, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
11:16AM	Q & A
11:18AM	<i>Topic 5B: Image-Guided, Minimally-Invasive Focal Treatment: Emerging Role in Patient Management:</i> John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
11:28AM	Q & A
11:30AM	<i>Topic 5C: Evolution of Surgical Data Analytics:</i> Archan Khandekar, MD, Assistant Professor (Urologic Oncology), University of Miami, Miller School of Medicine, Desai Sethi Urology Institute
11:40AM	Q & A
11:42AM	Topic 6: Human-AI Interaction in Prostate Cancer Diagnosis: Evis Sala, MD, PhD, FRCR, FRCP, Professor of Radiology, Università Cattolica del Sacro Cuore, Rome, Italy
11:52AM	Q & A

11:54AM	Topic 7: Optimal Management of Patients Presenting with Locally Advanced Prostate Cancer in 2026: Raja B. Khauli, MD
12:04PM	Q & A
12:06PM	Topic 8: Recurrent Disease
12:06PM	<i>Topic 8A: Principles of Focal Salvage Treatment for Radiorecurrent Prostate Cancer – Is it Feasible?</i> Giancarlo Marra, MD, Consultant Urologist and Assistant Professor, Division of Urology, AOU Citta Della Salute e Della Scienza and University of Turin, Italy
12:16PM	Q & A
12:18PM	<i>Topic 8B: NCI Working Group Recommendations on Biomedical Cancer Recurrence:</i> David Einstein, MD, Assistant Professor, Harvard Medical School, and Attending Physician, Beth Israel Deaconess Medical Center Genitourinary Medical Oncology Program
12:28PM	Q & A
12:30PM-1:00PM	<i>Panel Discussion: Integration of Precision Diagnosis and Treatment</i>
1:00PM-1:30PM	VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)
1:30PM-2:00PM	LUNCH BREAK
2:00PM	SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
	Moderators:
	Steven Eric Finkelstein, MD, DABR, FACRO, National Director of the Center of Advanced Radiation Excellence (CARE) and Director Radiation Oncology Research, Associated Medical Professionals/ US Urology Partners, Chair of Board, The Luther Brady Foundation of the American College of Radiation Oncology (ACRO), Board of Chancellors, American College of Radiation Oncology (ACRO)
	Raluca Mititelu, MD, PhD, Lecturer, Carol Davila University of Medicine and Pharmacy, Bucharest; and Clinic of Nuclear Medicine, Central Military Emergency University Hospital, Bucharest, Romania
	David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program
2:05PM	Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
2:05PM	<i>Topic 1A: Best Practices for Clinical Trials in Patients with Advanced Prostate Cancer: Recommendations of the Prostate Cancer Working Group 4:</i> David Nanus, MD
2:15PM	Q & A
2:17PM	<i>Topic 1B: The Earlier Use of Radio Pharmaceuticals in Prostate Cancer:</i> Marc B. Garnick, MD, Director of Cancer Community Services, BIDMC; Gorman Brothers Professor of Medicine at Harvard Medical School; and Editor in Chief, <i>Harvard Medical School Prostate Disease Report</i>
2:27PM	Q & A
2:29PM	<i>Topic 1C: Immunotherapy - Review and Update:</i> Sandy Srinivas, MD, Medical Oncologist, Stanford Health Care; Professor of Medicine (Oncology) and Urology, Stanford University; and Vice Chair, NCCN Panel for Prostate Cancer Treatment
2:39PM	Q & A
2:41PM	<i>Topic 1D: AI and Sequencing of Treatment:</i> Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors
2:51PM	Q & A

2:53PM-3:10PM	<i>Topic 1E: Emerging Advances in Precision Radiation Treatment and Immunotherapy:</i> Steven E. Finkelstein, MD, and Patrick Soon-Shiong, MD (TBC), Executive Chairman and Global Chief Scientific and Medical Officer, ImmunityBio
3:10PM-3:40PM	<i>Panel Discussion: Standard and Emerging Treatment</i>
3:40PM-4:10PM	COFFEE BREAK
4:10PM	Topic 2: Molecular Imaging and Theranostics
	Guest Moderator: Akram Al-Ibraheem, MD, Chairman, Department of Nuclear Medicine & PET/CT; Director, Nuclear Medicine Training Programs; and Head, Thyroid Cancer Multidisciplinary Team, King Hussein Cancer Center; President, Asia-Oceania Federation of Nuclear Medicine & Biology (AOFNMB); and President, Jordanian Society of Nuclear Medicine (JOSNM), Amman, Jordan
4:10PM	<i>Topic 2A: PSMA-PET Metrics for Outcome Prediction in Patients with mCRPC:</i> Sungmin Woo, MD, PhD
4:20PM	Q & A
4:22PM	<i>Topic 2B: Integration of Molecular Imaging and Treatment:</i> Andrei Iagaru, MD, Professor of Radiology and Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program, Stanford University
4:32PM	Q & A
4:34PM	<i>Topic 2C: Response Assessment with PSMA PET: Where We Stand and What Can be Achieved?</i> Vikas Prasad, MD, PhD, Associate Professor of Radiology, Director of Clinical Theranostics, Center for Clinical Theranostics Research, Division of Nuclear Medicine, Mallinckrodt Institute of Radiology; and Co-Chair, Theranostics Program, Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri
4:44PM	Q & A
4:46PM-5:00PM	<i>Panel Discussion: Molecular Imaging and Theranostics</i>
5:00PM-5:30PM	General Discussion
5:30PM-6:00PM	VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)

THURSDAY, OCTOBER 8, 2026

8:00AM	SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
	Moderators:
	David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York
	Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
	Giovanni Lughezzani, MD, Staff Physician, Department of Urology, Humanitas Clinical and Research Hospital, Rozzano (MI), and Associate Professor, Humanitas University, Milan, Italy
	Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
8:10AM	Topic 1: Overview of Focal Treatment: Mark Emberton, MD
8:20AM	Q & A

8:22AM	Topic 2: Current Clinical Trials
8:22AM	<i>Urologic Perspective: Clinical Trials in Focal Treatment at NIH and Emerging Role of Intraprostatic Drug Delivery:</i> Peter Pinto, MD, National Institutes of Health, Director of the Urologic Oncology Fellowship Program at the National Cancer Institute
8:32AM	Q & A
8:34AM	<i>Radiologic Perspective: Multicentre Trials on Focal Therapy:</i> Jurgen Futterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud University Medical Center, Nijmegen; and Professor, Robotics and Mechanics Group, University of Twente, The Netherlands
8:44AM	Q & A
8:46AM	Topic 3: AI and Focal Treatment
	<i>Quantitative MRI Reading, AI Derived Algorithms for ECE/BCR, and AI Use in MRI Directed Treatment of Prostate Cancer:</i> Victoria Bird, MD, President and Founder of Urologic Integrated Care, Gainesville, FLA; Staff Urologic Surgeon, HCA Florida North Florida Hospital; CEO, Urology Division, Research Group, National Medical Association; and Former Affiliate Professor of Engineering, Biomedical Engineering, College of Engineering, and Former Assistant Professor, Department of Urology, College of Medicine, University of Florida
8:56AM	Q & A
8:58AM	<i>Multi-Modal AI:</i> Rakesh Shiradkar, PhD, Assistant Professor, Biomedical Engineering and Informatics, Indiana University Indianapolis, Adjunct Assistant Professor, Radiology & Imaging Sciences, Pathology & Lab Medicine, Urology & Associate Member, IU Simon Comprehensive Cancer Center, Indiana University School of Medicine
9:08AM	Q & A
9:10AM	Topic 4: Current State of Irreversible Electroporation (IRE) and Imaging in Prostate Cancer Focal Therapy: Professor Phillip Stricker M.B., B.S (N.S.W.) (Hons), F.R.A.C.S. AO, Conjoint Professor, UNSW and Western Sydney University; Chairman, Department of Urology, St Vincents Campus; Director, St Vincents Prostate Cancer Research Centre; and Emeritus Fellow Garvan Institute
9:20AM	Q & A
9:22AM	Topic 5: Is Focal Treatment Appropriate for High-Risk Prostate Cancer? Xiaosong Meng, MD, PhD, Dedman Family Scholar in Clinical Care, Assistant Professor, Department of Urology, UT Southwestern Medical Center
9:32AM	Q & A
9:34AM	Topic 6: Comparative Analysis and Clinical Utility of the Current Modalities in Therapeutic Ablation for Prostate Cancer: Alessandro Marquis, MD, FEBU, Urology Clinic, Department of Surgical Sciences, Molinette Hospital and University of Turin
9:44AM	Q & A
9:46AM-10:20AM	<i>Panel Discussion</i>
10:20AM-10:40AM	COFFEE BREAK
10:40AM	Topic 7: Addressing Fundamental Challenges in Clinical Evaluation, Acceptance and Adoption of Image-Targeted Treatment- Perspective from the AdMeTech Foundation's International Working Group
10:40AM	<i>Review and Update – Imaging for Improving Post-Ablation Assessment and Developing Short-Term Patient Outcomes:</i> Faina Shtern, MD
10:50AM	<i>Current Approaches to MRI Reporting After Focal Treatment:</i> Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University
11:00AM	Q & A

11:02AM	<i>The Ablation Site Imaging (AIM) Multicenter Diagnostic Accuracy Study of MRI After Focal Therapy: Alexander Light, MBBS, MRCS, NIHR Doctoral Fellow and Urology Registrar, Imperial Prostate, Imperial College London</i>
11:12AM	Q & A
11:14AM	<i>A New Scoring System for PSMA Imaging and PSMA/MRI Integration for Patient Evaluation after Focal Treatment: Development and Preliminary Data: Giovanni Lughezzani, MD</i>
11:24AM	Q & A
11:26AM-12:00PM	Panel on MRI Reporting After Partial Ablation and Scoring System (PI-MAPS) – Rationale, Background, & Recommendations: Francesco Giganti, MD, PhD, Associate Professor of Radiology, Faculty of Medical Sciences, University College London, and Honorary Consultant Radiologist, University College London Hospitals Sangeet Ghai, MD, Professor and Trachtenberg Haque Chair in Image Guided Prostate Therapy Research, Director of Research, Joint Department of Medical Imaging, University Health Network – Mt Sinai Hospital – Women’s College Hospital, University of Toronto, Canada Daniel Margolis, MD
12:00PM-12:30PM	Panel on Molecular Imaging After Focal Treatment – Rationale, Background, Emerging Data and Next Steps: Andrei Iagaru, MD; Irene Burger, MD, Head of Nuclear Medicine, Kantonsspital Baden, Baden Switzerland; Attending Nuclear Medicine, University Hospital Zurich, Switzerland; and Andrea Di Giorgio, MD
12:30PM-1:00PM	GENERAL DISCUSSION
1:00PM-1:30PM	VIP NETWORKING DISCUSSION FOR SPEAKERS AND SPONSORS (BY INVITATION ONLY)
1:30PM-2:00PM	LUNCH BREAK
2:00PM	KEYNOTE PRESENTATION: We Still Don’t Understand the Prostate Cancer Genome: Why Not? Paul Boutros, PhD, MBA
2:15PM	Q & A
2:30PM-3:00PM	PRESENTATION OF WINNING ABSTRACTS
3:00PM-4:00PM	GENERAL DISCUSSION
4:00PM	ADJOURN